argenx
Logotype for argenx SE

argenx (ARGX) investor relations material

argenx 3rd Annual Guggenheim Healthcare Innovation Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for argenx SE
3rd Annual Guggenheim Healthcare Innovation Conference summary10 Nov, 2026

Business development and capital allocation

  • UNP acquisition announced the prior day, subject to customary closing conditions; the partnership dates back ~2 years and includes work on an oral peptide.

  • Strategy follows biology and differentiated patient impact; peptides and new modalities are viewed as important areas for science-led expansion.

  • VYVGART and the FcRn franchise are expected to support growth in the short, medium and long term; Empa, Forte and UNP add growth pillars for this and the next decade under Vision 2030.

  • BD will primarily target Phase I/II assets to support next-decade revenue growth, with multi-indication potential and reduced single-indication risk; commercial-stage assets remain possible selectively.

  • Strong P&L and balance sheet support continued, disciplined BD and capital allocation.

VYVGART commercial momentum

  • MG and CIDP base businesses continue to grow; 20% of MG patients are on a biologic, while 80% remain on older therapies, and VYVGART leads biologic growth.

  • Seronegative gMG approval came in May; payer policies now cover >90% of covered lives, supporting Q3 uptake and a prescriber halo that also brought AChR-positive patients to VYVGART.

  • MG treatment is typically an add-on, while CIDP requires switching from entrenched IVIG; initial CIDP uptake is strongest in refractory or inadequately treated patients, with a longer-term goal of moving earlier in treatment.

  • PFS is the clear US growth driver and is rapidly becoming dominant outside the US; Germany PFS utilization is in the high 90% range, Hytrulo use is declining, and US IV business remains strong and roughly flat.

  • Q3 gross-to-net reached 22% and is gradually rising with PFS growth and Medicare Part D rebates; higher drug use per PFS patient offsets the higher gross-to-net, with no net contribution drag.

Pipeline and launch plans

  • Potential 2027 launches include pediatric and ocular MG extensions, an autoinjector, IMNM and MMN; pediatric and ocular extensions and the autoinjector are expected to support MG growth.

  • Ocular MG could expand the label beyond gMG; the estimated VYVGART-addressable ocular population is 7,000 patients.

  • IMNM filing planned before end-2026; a PDUFA date was expected to be announced in early January. The indication includes 20,000 patients with no approved treatment, and was identified as the largest potential growth contribution among launches.

  • Empa Phase III MMN results are due in December; if positive, launch is hoped for in the later part of 2027. Non-inferiority versus IVIG is the primary endpoint and considered sufficient for a successful launch; superiority is secondary.

  • IMNM requires rheumatology commercial capabilities; marketing and medical affairs roles were being posted, with field-force hiring planned for 2027. DM requires another FDA-requested study, with a potential launch closer to decade-end.

  • Multiple Phase III trials for Forte's FB102 are planned to start in 2027 across multiple indications, with additional indications expected over time.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next argenx earnings date

Logotype for argenx SE
Jefferies Global Healthcare Conference17 Nov, 2026
argenx
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next argenx earnings date

Logotype for argenx SE
Jefferies Global Healthcare Conference17 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

argenx SE is a biotechnology firm based in Amsterdam, the Netherlands, specializing in the development of innovative therapies for autoimmune diseases. The company has developed a range of antibody-based medicines focusing on severe autoimmune conditions. Its flagship product, efgartigimod, targets various autoimmune disorders including myasthenia gravis and immune thrombocytopenia. argenx SE also collaborates with several partners to expand its research and development capabilities in immunology and oncology, highlighting its engagement in strategic alliances to advance its pipeline of therapeutic antibodies. The company is headquartered in Amsterdam, the Netherlands, and its shares are listed on the NASDAQ.